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Victor G. Davila-Roman,4,5 Alan D. Waggoner,4,5 Dominic N. Reeds,6 Sherry Lassa-Claxton,2
Melissa J. Krauss,7 Linda R. Peterson,5 and Kevin E. Yarasheski1,2
Abstract
Our objective was to determine if the presence of metabolic complications (MC) conveyed an additional risk for left
ventricular (LV) dysfunction in people with HIV. HIV+ and HIV- men and women were categorized into four
groups: (1) HIV+ with MC (43– 7 years, n= 64), (2) HIV+ without MC (42– 7 years, n= 59), (3) HIV- with MC
(44– 8 years, n= 37), or (4) HIV- controls without MC (42– 8 years, n= 41). All participants underwent two-
dimensional (2-D), Doppler, and tissue Doppler echocardiography. Overall, the prevalence of systolic dysfunction
(15 vs. 4%, p= 0.02) and LV hypertrophy (9 vs. 1%, p= 0.03) was greater in HIV+ than in HIV- participants.
Participants with MC had a greater prevalence of LV hypertrophy (10% vs. 1%). Early mitral annular velocity
during diastole was significantly ( p< 0.005) lower in groups with MC (HIV+/MC+ : 11.6– 2.3, HIV-/MC+ :
12.0– 2.3 vs. HIV+/MC- : 12.4– 2.3, HIV-/MC- : 13.1– 2.4 cm/s) and tended to be lower in groups with HIV
( p= 0.10). However, there was no interaction effect of HIV and MC for any systolic or diastolic variable. Regardless
of HIV status, participants with MC had reduced LV diastolic function. Although both the presence of MC and HIV
infection were associated with lower diastolic function, there was no additive negative effect of HIV on diastolic
function beyond the effect of MC. Also, HIV was independently associated with lower systolic function. Clinical
monitoring of LV function in individuals with metabolic risk factors, regardless of HIV status, is warranted.
Introduction
Left ventricular (LV) dysfunction is common in late-stage acquired immune deficiency syndrome (AIDS),1,2
but since the advent of combination antiretroviral therapy
(cART) the incidence of AIDS-related cardiomyopathy has
significantly declined.3,4 Despite these improvements, evi-
dence from both industrialized5–12 and developing countries9
indicates that the prevalence of subclinical LV dysfunction in
individuals with well-controlled HIV infection may approach
50%12,13 and may represent a newly recognized comorbid
condition.14,15
Mechanisms for subclinical LV function abnormalities in
HIV are unclear. The HIV virus and its related proteins16,17
may play a role in LV dysfunction; however, other factors also
likely contribute to impaired contractility.15 HIV infection and
cART are associated with adverse metabolic risk factors or
complications, frequently referred to as HIV-related meta-
bolic syndrome, that are related to increased risk for myo-
cardial infarction in individuals with HIV.18 This syndrome
includes insulin resistance,19,20 dyslipidemia,21,22 and central
fat accumulation,23,24 all characteristics of non-HIV-associated
metabolic syndrome, a condition associated with higher car-
diovascular (CV) disease risk.25–27 In HIV -people, the meta-
bolic syndrome is associated with an increased risk for CV
morbidity (including coronary artery disease and congestive
heart failure) and mortality.25 Recent evidence has also linked
metabolic risk factors to subclinical LV dysfunction in HIV -
individuals.25,26,28,29 LV dysfunction is an important predictor
of overall mortality in the general population.30
The objective of this study was to determine if the pres-
ence of metabolic risk factors/complications similar to the
metabolic syndrome in the general population conveys an
additional risk for LV dysfunction in men and women in-
fected with HIV. We hypothesized that in participants with
HIV infection, metabolic risk factors present an additive risk
for LV systolic and diastolic dysfunction over HIV infection
alone.
1Program in Physical Therapy, 2Division of Endocrinology, Metabolism, and Lipid Research, 3Division of Infectious Disease, 4Cardio-
vascular Imaging and Clinical Research Core Laboratory, 5Cardiovascular Division, 6Division of Geriatrics and Nutritional Science, and
7Division of Biostatistics, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri.
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HIV-infected men and women were recruited from the
AIDS Clinical Trials Unit, the Infectious Diseases Clinics at
Washington University School of Medicine (WUSM), and the
surrounding metro St. Louis community. HIV - men and
women were recruited from the Division of Cardiology, the
Department of Radiology, and through a volunteer recruit-
ment service at WUSM. Participants were categorized to one
of four groups: (1) HIV-positive participants currently taking
cART with three or more metabolic risk factors/metabolic
complications (MC), (HIV +/MC + ; n= 64), (2) HIV-positive
participants taking cART having one or no metabolic risk
factors/complications (HIV +/MC- ; n = 59), (3) HIV-negative
participants with three or more metabolic risk factors/com-
plications (HIV -/MC+ ; n= 37), or (4) HIV-negative healthy
controls with similar age, gender, and activity level with one
or no metabolic risk factors/complications (HIV -/MC - ;
n = 41). For both HIV + and HIV - groups, metabolic compli-
cations were defined according to a modification of the
amended National Cholesterol Education Program’s Adult
Treatment Panel III (ATP-III) guidelines and a definition of
HIV metabolic syndrome.
All participantswithMCmet three ormore of the following
criteria: (1) body mass index (BMI) ‡ 30 kg/m2; (2) fasting
serum glucose ‡ 100mg/dl OR fasting serum insulin
‡ 13lU/ml OR use of glucose-lowering medication; (3) fast-
ing serum triglyceride ‡ 150mg/dl; (4) resting blood pres-
sure: systolic ‡ 130 OR diastolic ‡ 85mm Hg OR
antihypertensive therapy; and (5) low high-density lipopro-
tein (HDL) ( < 40mg/dl in men or < 50mg/dl in women)
(Fig. 1).31 Most of the prior research examined the prevalence
of the metabolic syndrome in HIV + individuals using the
traditional ATP-III criteria of impaired fasting glucose32–35;
however, others have used additional criteria36,37 to define
impaired fasting glucose. We included fasting insulin as a
criterion for abnormal glucose metabolism because HIV in-
fection is associated with fasting hyperinsulinemia but normal
glycemia, while typical metabolic syndrome (HIV- ) is asso-
ciated with fasting hyperinsulinemia and hyperglycemia.24 In
addition, due to the known relationship between insulin re-
sistance and diastolic dysfunction,38 we believed it was im-
portant to include a measure of fasting insulin in order not to
exclude participants who had insulin resistance but normal
fasting glucose.
BMI was used as a criterion for abnormal body composi-
tion as waist circumference (WC) was not available for all
participants. The World Health Organization defines ab-
dominal adiposity as BMI > 30 kg/m2 in the definition of the
metabolic syndrome and abdominal adiposity is common in
HIV + adults, so it is likely a valid surrogate for WC. In ad-
dition, although unknown in HIV, the prevalence of the
metabolic syndrome in the general population is essentially
identical whether BMI or WC is used.39 While differences in
the prevalence of abdominal adiposity between HIV + and
HIV - individuals with the metabolic syndrome are not
clear,32,37 increased BMI is associated with a higher preva-
lence of ATP-III-defined metabolic syndrome in HIV + peo-
ple suggesting that abdominal adiposity is an important
component of HIV-associated metabolic syndrome. Re-
gardless, abdominal obesity was recently determined not to
be an obligatory criterion for the definition of the metabolic
syndrome.40
HIV-infected participants had been taking their current
cART regimen for ‡ 6 months (Table 1). For HIV +/MC+ , 30
(47%) were on a protease inhibitor (PI)-based regimen, 24
(38%) were on a nonnucleoside reverse transcriptase inhibitor
(NNRTI)-based regimen, one (2%) was on both a PI- and
NNRTI-based regimen, one (2%) was on triple NRTI therapy,
two (3%) were not on therapy, and six (9%) were unknown
due to loss of contact. For HIV +/MC- , 27 (46%) were on a PI-
based regimen, 29 (49%) were on an NNRTI-based regimen,
one (2%) was on triple NRTI therapy, one (2%) was not on
therapy, and one (2%) was unknown due to loss of contact.
There were no differences in the major types of NRTI between
HIV +/MC + and HIV +/MC - (zidovudine: 20 vs. 24%, la-
mivudine: 34 vs. 30%, tenofovir: 39 vs. 51%). Other types of
NRTI occurred in small percentages in each group. All HIV-
infected participants had plasma HIV RNA that was unde-
tectable (< 400 copies/ml) except for nine HIV +/MC+ and
eight HIV +/MC - participants who had viral loads of 401–
50,000 copies RNA/ml (Table 1). No participants had a cur-
rent opportunistic infection or CD4 count below 200 cells/ll.
The duration of HIV infection and time on cART were similar
between groups (Table 1).
Participants were excluded if they consumed more than
three alcohol-containing beverages per week, were coinfected
with hepatitis C or B, reported using recreational drugs for 6
months prior to enrollment, had documented type 2 diabetes
or coronary artery disease, and were not weight stable (less
than 2% weight change in the 3 months prior to the study).
None of the participants participated regularly (more than
two times/week) in physical activities that would constitute
exercise training. HIV +/MC - had a higher percentage of
current tobacco users than the other groups (Table 1). The
Human Studies Committee at Washington University ap-
proved the study and all participants provided informed


































FIG. 1. Percent meeting individual component of metabolic
complication criteria. BMI, body mass index; IFG, impaired
fasting glucose; INS, plasma insulin; GluMed, glucose-
lowering medication; TG, triglyceride; HDL, high-density
lipoprotein; SBP, systolic blood pressure; DBP, diastolic
blood pressure; HTNMed, hypertension medication.
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Fasting blood chemistry, glucose tolerance,
and body composition
Upon enrollment, participants provided a comprehensive
medical history and underwent a physical examination,
fasting blood chemistry, complete blood cell count, plasma
HIV RNA quantification (Roche Amplicor HIV-1 Monitor,
Indianapolis, IN), and serum lipid, lipoprotein, and endocrine
profiles [insulin, triglycerides (TG), total-, LDL-, and HDL-
cholesterol]. Plasma analyses were performed as previously
described.41
Resting echocardiography
Indices of LV structure and function were measured by
two-dimensional (2-D), Doppler, and tissue Doppler imaging
(TDI) by a blinded echocardiographer. 2-D measurements
included LV volumes and end diastolic and end systolic
volumes from the apical four- and two-chamber views
(method of disks). LV ejection fractions were determined by
the biplane method and by the area-length method, respec-
tively, normalized to body surface area.42 LV mass was mea-
sured by the 2-D-directed M-mode-derived cubed method.43
Pulsed wave Doppler (PWD) transmitral velocities were
obtained at the mitral leaflet tips according to established
guidelines.44 Indices of LV diastolic function include the peak
transmitral early diastolic (E) and late diastolic atrial (A) inflow
velocities, the ratio of the peakmitral E/A velocities, and the E-
wave deceleration time.45 Isovolumic relaxation time was de-
termined by measuring the time from the closure of the aortic
valve to the onset ofmitral flow. Resting heart rate, systolic and
diastolic blood pressures, and mean arterial pressure were
measured at the time of echocardiography.
TDI was determined by the placement of a 3-mm sample
volume at the lateral and septal mitral annulus in the four-
chamber view. Systolic (S¢) and early diastolic (E¢) myocardial
wall velocities from the two sites were averaged to derive S¢
and E¢.46 Measurement at the lateral and septal annulus has
been shown to have high specificity for indicating relatively
load-independent impaired relaxation.47,48 Measurements
represent the average of three to five cycles. We chose these
diastolic measures because the E/A ratio is a load-dependent
measure of the pressure gradient between the left atrium and
LV (influenced by alterations in relaxation); mitral valve an-
nular velocity (E¢) is a relatively load-independent measure of
LV relaxation; isovolumic relaxation time is a load-dependent
measure of LV relaxation; E-wave deceleration time is an in-
direct measure of LV stiffness; and E/E¢ is an estimate of LV
filling pressures.47
Systolic dysfunction was defined by the LV ejection fraction
categorized as normal (‡ 55%), mildly decreased (45–54%),
moderately decreased (35–44%), and severely depressed
(< 35%) as defined byMondy et al.14 Diastolic dysfunction was
defined on the basis of Doppler peak early (E) and late (A)
diastolicmitral inflow velocity, mitral inflowdeceleration time,
and mitral annular velocity (E¢) averaged from the lateral wall
and septum.49,50 Left ventricular hypertrophy was determined
by M-mode echocardiography values for LVmass index ‡ 127
for men and ‡ 100 for women.43
Statistics
Differences in demographic variables among the four
groups (HIV +/MC + , HIV +/MC - , HIV -/MC + , and HIV -/
MC - ) were tested using Fisher’s exact tests for categorical
variables and one-way analysis of variance (ANOVA) for
continuous variables. Differences in dependent variables of
interest between MC +/MC- and HIV +/HIV - were tested
first using ANOVA, including the HIV, MC, and the
Table 1. Demographic Characteristics of Study Participants
HIV - HIV +
MC - MC+ MC - MC+
Variable (n = 41) (n = 37) (n = 59) (n = 64) p
Age (years) 42– 6 44 – 8 42 – 7 43 – 7 0.739
Male, n (%) 35 (85) 33 (89) 45 (76) 53 (83) 0.433
African-American, n (%) 14 (34) 7 (19) 31 (53) 29 (45) 0.005
Other nonwhite, n (%) 0 (0) 0 (0) 0 (0) 2 (3)
CD4 (cells/ll) N/A N/A 515– 206 537– 260 —
Median viral load (copies/ml) N/A N/A UD (0–33,872) UD (0–48,600) —
Median HIV duration (months) N/A N/A 133 (14–262) 121 (23–272) —
Median cART use (months) N/A N/A 71 (3–246) 73 (4–237) —
Current tobacco use, n (%) 10 (24) 10 (27) 25 (43) 14 (22) 0.064
Antiretroviral therapy, n (%)
NRTI N/A N/A 56 (95) 60 (94) —
NNRTI N/A N/A 26 (44) 29 (45) —
PI N/A N/A 32 (54) 39 (61) —
Fusion NA NA 0 (0) 2 (3) —
Medical therapy, n (%)
HTN 6 (15) 16 (43) 4 (7) 15 (23) < 0.001
Lipid lowering 3 (7) 10 (27) 2 (3) 16 (25) < 0.001
HIV, human immunodeficiency virus; MC, metabolic complications; cART, combined antiretroviral therapy; UD, undetectable< 400
copies/ml; BMI, body mass index; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI,
protease inhibitor; Fusion, fusion inhibitor; HTN, hypertension.
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interaction of the two, with Tukey Honestly Significant Dif-
ference (HSD) testing for pairwise comparisons. Groups dif-
fered slightly by race; thus, all dependent variables were also
assessed among the groups using analysis of covariance
(ANCOVA), adjusting for race. Again, the models included
HIV, MC, and their interaction, with Tukey HSD testing for
pairwise comparisons. Groups also differed by BMI, but this
was expected as BMI is reflected in MC status. Therefore, BMI
was not included in the ANCOVAs. A p-value< 0.05 was
considered statistically significant.
For variables where MC was a significant predictor, mul-
tivariable regression was used to explore which of the meta-
bolic criteria that define MC status (i.e., BMI, fasting glucose,
fasting insulin, systolic blood pressure, diastolic blood pres-
sure, and triglycerides) was the strongest predictor of LV
dysfunction. Models were built in a manual backward step-
wise fashion, retaining variables with p< 0.05 in the final
model. Interactions of final predictors with HIV status were
also assessed to determine whether the effect of the predictors
differed by HIV status. All data are expressed as means – SD
unless specified otherwise. SAS version 9.2 (SAS, Cary, NC)
was used for all analyses.
Results
Demographics
The groups were similar in age but differed significantly
by race (Table 1). Mean CD4 count and median viral load,
time since HIV diagnosis, and time on cART were similar in
the HIV + groups (Table 1). HIV + groups tended to have a
higher percentage of tobacco users than groups without
HIV (Table 1). A greater percentage of HIV -/MC+ were
taking hypertension medications than other groups and a
greater percentage of participants in the MC + groups were
taking a lipid-lowering medication than participants in the
MC - groups (Table 1).
Body composition and metabolic characteristics
BMI and DBP were greater in HIV -/MC + than all other
groups (Table 2). Fasting plasma insulin, HOMA, triglycer-
ides, and systolic blood pressure were greater in MC + groups
than MC - groups, but did not differ by HIV status. High-
density lipoprotein (HDL) cholesterol was lower in MC +
groups than in MC - groups. Fasting plasma glucose was
lower in HIV -/MC - than all other groups, and was lower in
HIV +/MC - than in HIV -/MC + . There were no differences
in fasting plasma total- and low-density lipoprotein choles-
terol levels among groups (Table 2).
Prevalence of clinical echocardiographic abnormalities
Overall, the prevalence of systolic dysfunction was
greater in HIV + participants (15%) than in HIV - partici-
pants (4%) ( p = 0.02). The prevalence of systolic dysfunction
was similar in those who had MC (10%) than in those who
did not (11%), irrespective of HIV status ( p = 0.82). The
prevalence of systolic dysfunction tended to be greater in
HIV +/MC + (14%) and HIV +/MC - (15%) compared to
HIV -/MC + (3%) and HIV -/MC - (5%) ( p = 0.11). Overall,
there was no significant difference in prevalence of diastolic
dysfunction between HIV + participants (33%) compared to
HIV - participants (23%), regardless of MC status ( p = 0.20),
or between those with (33%) and without (25%) metabolic
complications, irrespective of HIV status ( p = 0.28). The
prevalence of diastolic dysfunction was similar among
HIV +/MC + (38%), HIV +/MC - (27%), HIV -/MC + (24%),
and HIV -/MC - (22%) ( p = 0.32). Those with HIV had a
higher prevalence of left ventricular hypertrophy (HIV + : 9%
vs. HIV - : 1%, p = 0.03) and those with MC (10%) had a
higher prevalence of left ventricular hypertrophy (LVH)
than those without MC (2%) ( p = 0.03). The prevalence of
LVH was 14% in HIV +/MC + , 3% in HIV +/MC - , 3% in
HIV -/MC + , and 0% inHIV -/MC - and tended to be higher
Table 2. Body Composition and Metabolic Characteristics
HIV - HIV + ANCOVA resultsa
MC - MC+ MC- MC+ HIV MC HIV*MC
Variable (n = 41) (n = 37) (n = 59) (n = 64) p p p
BMIb 27.3 – 4.2 33.8 – 4.7 25.7 – 3.6 28.7 – 5.4 < 0.001 < 0.001 0.005
Glucose (mg/dl)c 81.4 – 10.4 96.3 – 19.2 88.7 – 6.9 92.1 – 8.1 0.315 < 0.001 0.001
Insulin (lU/ml) 6.8 – 4.8 19.4 – 13.4 8.1 – 5.0 17.4 – 13.4 0.766 < 0.001 0.248
HOMA 1.4 – 1.0 4.9 – 3.6 1.8 – 1.2 4.1 – 3.2 0.555 < 0.001 0.081
TG (mg/dl) 116.7– 106.5 213.4 – 134.1 116.2– 54.9 242.3– 169.2 0.251 < 0.001 0.366
HDL (mg/dl) 53.8 – 13.4 39.3 – 7.4 49.4 – 12.9 37.5 – 8.4 0.009 < 0.001 0.489
Total cholesterol (mg/dl) 183.7– 31.0 184.8 – 30.8 170.2– 31.9 186.5– 34.1 0.185 0.059 0.113
LDL (mg/dl) 106.0– 26.5 105.7 – 29.8 97.7 – 27.8 104.0– 32.0 0.195 0.441 0.463
SBP (mm Hg) 117.3– 10.9 125.8 – 11.2 115.8– 12.4 125.3– 13.5 0.411 < 0.001 0.812
DBP (mm Hg)d 75.3 – 7.8 84.2 – 7.0 75.3 – 7.5 77.6 – 9.7 0.002 < 0.001 0.005
aAdjusted for race.
bSignificant pairwise comparisons for BMI: HIV-/MC- vs. HIV -/MC+ p< 0.001; HIV -/MC+ vs. HIV+/MC- p< 0.001; HIV -/MC+ vs.
HIV+/MC+ p< 0.001; HIV+/MC- vs. HIV+/MC+ p = 0.001.
cSignificant pairwise comparisons for glucose: HIV-/MC- vs. HIV -/MC+ , p< 0.001; HIV -/MC- vs. HIV+/MC- p = 0.008; HIV-/MC-
vs. HIV +/MC+ p< 0.001; HIV -/MC+ vs. HIV+/MC-p= 0.013.
dSignificant pairwise comparisons for DBP: HIV -/MC- vs. HIV-/MC+ p< 0.001; HIV-/MC+ vs. HIV+/MC- p < 0.001; HIV-/MC+ vs.
HIV+/MC+ p< 0.001.
HIV, human immunodeficiency virus; MC, metabolic complications; BMI, body mass index; TG, triglyceride; HDL, high-density
lipoprotein; LDL, low-density lipoprotein; SBP, systolic blood pressure; DBP, diastolic blood pressure.
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in HIV +/MC + than HIV +/MC - ( p = 0.06), HIV -/MC +
( p = 0.09), and HIV -/MC - ( p = 0.01).
LV structure and function
There were significant independent effects of HIV and MC
on LV mass index. LV mass index was higher in HIV + par-
ticipants and for MC + participants (Table 3). HIV had a sig-
nificant or trended toward a significant independent negative
effect on several systolic function variables including ejection
fraction, fractional shortening, LV ejection time, and annular
velocity measured during systole (Table 3). Both HIV infec-
tion and the presence ofMChad significant or trended toward
having an independent negative effect on several indices re-
flective of diastolic function, e.g., lower E/A ratio (Table 3)
and lower early diastolic mitral annular velocity during di-
astole (E¢) in HIV + groups and in MC + groups. However,
there was no interaction effect of HIV andMC for any systolic
or diastolic variable (i.e., effects of HIV did not significantly
differ by MC status).
Components of MC as predictors of LV function
In backward step-wise multivariable regression models of
LV structure and function, HIV status and components of MC
were used as predictors (i.e., BMI, fasting glucose, fasting
insulin, systolic blood pressure, diastolic blood pressure, tri-
glyceride) (Table 4). For prediction of reduced annular ve-
locity during systole (S¢), higher fasting glucose and HIV
infection were independent predictors; interactions with HIV
were not significant. For prediction of annular velocity during
diastole (E¢), higher fasting insulin and HIV infection inde-
pendently predicted reduced E¢. In a similar model, higher
fasting insulin, diastolic blood pressure, and HIV infection
remained independently associatedwith a reduced E/A ratio.
The interactions of fasting glucose and diastolic blood pres-
sure with HIV were not significant. Finally, in the model
predicting LV mass index, systolic blood pressure, BMI, HIV
infection, and the interaction of HIV infection and BMI re-
mained in the final model. The interaction of BMI and HIV
suggested that a negative association of BMI with LV mass
index was largely confined in HIV + participants, but not in
HIV - participants. There were no significant associations
with cART class (PI vs. no-PI) and LV outcome variables in
HIV + participants.
Discussion
This is the first study to examine the potential relationships
among well-controlled HIV infection and metabolic risk fac-
tors for cardiovascular disease and LV function, and compare
these to HIV-negative men and women with and without
similar metabolic risk factors. The main finding was that HIV
infection and metabolic risk factors have independent
negative associations with diastolic function. However, well-
controlled HIV infection does not act additively or synergis-
tically with indices of metabolic risk that adversely affect
diastolic function. In addition, it appears that HIV also has an
independent negative association with systolic function and
LV mass. An adverse relationship of HIV infection with LV
function and mass has been previously reported in primate
models of simian immunodeficiency (SIV) and in humans
with HIV.9,16,17 Furthermore, other studies have shown that
metabolic risk factors have an independent negative rela-
tionship with LV function and mass in HIV-negative indi-
viduals.27–29 However, no previous study has examined the
potential additive effect of these variables on the relationship
Table 3. Echocardiographic Parameters
HIV - HIV + ANCOVA resultsa
MC- MC+ MC- MC+ HIV MC HIV*MC
Variable (n = 41) (n = 37) (n = 59) (n = 64) p p p
BSA (m2) 2.0 – 0.3 2.2 – 0.2 2.0 – 0.3 2.1 – 0.4 0.039 < 0.001 0.203
HR (bpm) 63.1 – 9.7 67.7 – 11.5 64.6 – 12.2 65.9 – 12.3 0.656 0.059 0.288
LV structure
LVM-mm (g) 166.4– 38.0 206.9– 49.6 183.2– 38.8 200.2– 47.8 0.615 < 0.001 0.058
LVMI (g/m2) 83.3 – 12.8 91.7 – 17.3 93.4 – 16.4 95.8 – 21.7 0.007 0.045 0.262
LV systolic function
EF (%) 62– 6 62– 6 59– 6 61– 7 0.022 0.405 0.535
FS (%) 31.3 – 6.5 33.1 – 4.8 33.7 – 6.2 34.7 – 6.0 0.093 0.161 0.532
LVET (ms) 300.8– 21.8 291.2– 28.7 291.1– 32.9 283.5– 33.9 0.056 0.060 0.827
S¢ (cm/s) 8.9 – 1.3 8.4 – 1.5 8.1 – 1.0 8.1 – 0.9 0.003 0.133 0.174
LV diastolic function
E-wave (cm/s) 71.6 – 11.5 72.0 – 17.2 68.9 – 15.6 67.4 – 15.4 0.035 0.950 0.583
E/A ratio 1.59 – 0.41 1.51 – 0.48 1.52 – 0.52 1.29 – 0.44 0.026 0.027 0.230
E¢ (cm/s) 13.1 – 2.4 12.0 – 2.3 12.4 – 2.3 11.6 – 2.3 0.105 0.005 0.795
E/E¢ 5.6 – 1.0 6.1 – 1.3 5.6 – 1.3 5.9 – 1.4 0.533 0.020 0.520
DT (ms) 199.2– 36.2 199.3– 38.0 199.7– 36.9 202.9– 35.6 0.556 0.832 0.739
IVRT (ms) 82.1 – 16.0 88.4 – 16.5 87.8 – 15.7 87.7 – 13.0 0.237 0.173 0.149
aAdjusted for race.
HIV, human immunodeficiency virus; MC, metabolic complications; BSA, body surface area; HR, heart rate; LVM-mm, left ventricular
mass measured by M-mode; LVMI, left ventricular mass index (LVM/BSA); EF, ejection fraction; LVET, left ventricular ejection time; FS,
fractional shortening; S¢, systolic myocardial velocity averaged from the lateral wall and septum; E¢, myocardial velocity during early diastole
averaged from the lateral wall and septum; DT, deceleration time; IVRT, isovolumic contraction time.
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with LV function in people living with well-controlled HIV.
Our data confirm previous reports from SIV-infected non-
human primates and HIV-infected humans that demon-
strated the adverse relationship among these chronic
infections and LV function.
The finding of no additional negative effect of HIV infection
on the relationship with diastolic function and LV mass in-
dexed for body surface area over the detrimental effects of
metabolic complications was surprising and contrary to our
hypothesis. It is unclear how the presence of metabolic com-
plications mediates impaired diastolic function. One metabolic
complication, obesity, is significantly related to diastolic dys-
function and increased LV mass.46 Specifically, there is im-
paired LV relaxation and increased LV end-diastolic pressure
with increased BMI.46 Although the mechanisms are not
completely clear, increased levels of reactive oxygen spe-
cies51,52 as well as lipid-induced apoptosis53 have been impli-
cated in the development of obesity-related impaired LV
relaxation. In the current study, HIV- participants with met-
abolic risk factors had greater BMI thanHIV+ participantswith
metabolic complications. Perhaps if the degree of obesity was
identically matched between metabolically complicated
groups, then greater impairments in LV function and mass
may have been detected in HIV+ participants. Also, in the
current study, we found a relationship between higher plasma
insulin (along with diastolic blood pressure) and lower dia-
stolic function among all participants (and in separate HIV+
and HIV- only analyses, data not shown) indicating that in-
sulin resistance may play a role in diastolic dysfunction re-
gardless of HIV infection. We previously reported
relationships between myocardial insulin resistance and re-
duced diastolic function in a smaller study of HIV+ men.54 A
positive association between insulin resistance and diastolic
dysfunction has also been shown in HIV- individuals.38
However, the mechanism for insulin resistance-mediated
diastolic dysfunction in humans with HIV remains to be
elucidated.
In the present study, HIV, and less commonly peripheral
metabolic risk factors, were associated with greater abnor-
malities in systolic and diastolic function. With the exception
of the E/A ratio, none of the measured parameters of systolic
and diastolic function was significantly predicted by both
HIV and metabolic risk factors; therefore, there is little evi-
dence for an additive or synergistic effect of HIV with the
presence of metabolic risk factors on LV function. Although
not fully understood, it appears that HIV replication16 may
mediate impaired diastolic dysfunction through the viral
glycoprotein 12055,56 and the CXCR4-iPLA2-p38 mitogen-
activated (MAP) kinase-troponin I inflammatory signaling
pathway.56–58 It is possible that peripheral metabolic com-
plications and HIV may mediate diastolic dysfunction
through a similar inflammatory pathway and therefore that is
the reason we did not see an additive effect of metabolic
complications with HIV in the current study. Metabolic syn-
drome is a proinflammatory state59 and the MAP kinase
pathway60 and other G-protein-associated pathways61 have
been implicated in playing a role in non-HIV metabolic syn-
drome and CVD. However, we did not measure serum in-
flammatory cytokines or obtain myocardial biopsies to
examine the effect of these inflammatory pathways on LV
function in the current study. In addition, 86% of the current
participants were virologically suppressed with cART.
There is some previous evidence that HIVmediates systolic
dysfunction. Systolic dysfunction was found in animal mod-
els that expressed increased amounts of HIV proteins62–64 and
in patients with advanced disease (i.e., increased plasma vi-
remia)65–67; however, it is unclear if HIV-associated systolic
dysfunction is mediated through a pathway similar to HIV-
associated diastolic dysfunction. Additional research in this
area, especially in HIV-infected individuals with HIV sup-
pression, is warranted.
LV mass was also independently associated with both HIV
infection and the presence of metabolic complications. The
association of LV mass with metabolic complications is in
agreement with previous studies in HIV - individuals.68
However, the presence of both HIV and metabolic compli-
cations did not result in greater increases in LV mass. The
finding of an independent effect of HIV is in agreement with
Table 4. Regression Results for Components of Metabolic Complications as Predictors
of Left Ventricular Function
Dependent variable Independent variables b SE p
Annular velocity during systole (S¢) Fasting glucose - 0.0001 0.0001 0.037
HIV infection (positive versus negative) - 0.006 0.002 0.001
Annular velocity during diastole (E¢) Fasting insulin - 0.0004 0.0001 0.005
DBP - 0.0008 0.0002 < 0.001
HIV infection (positive versus negative) - 0.008 0.003 0.015
E/A ratio Fasting insulin - 0.0077 0.0029 0.009
DBP - 0.0137 0.0038 < 0.001
HIV infection (positive versus negative) - 0.186 0.068 0.007
LVMI SBP 0.3187 0.0972 0.001
BMI 0.4369 0.3691 0.238
HIV infection (positive versus negative) 51.167 14.152 < 0.001
HIV infection * BMI - 1.549 0.479 0.001
Components of metabolic complications used as predictors were BMI, fasting glucose, fasting insulin, SBP, DBP, and TG. Results shown are
from backward step-wise multivariable regression, retaining variables with p < 0.05 in the final model.
S¢, systolic myocardial velocity averaged from the lateral wall and septum; HIV, human immunodeficiency virus; E¢, myocardial velocity
during early diastole averaged from the lateral wall and septum; DBP, diastolic blood pressure; LVMI, left ventricular mass index; SBP,
systolic blood pressure; BMI, body mass index.
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Hsue et al.9 who reported that HIV infection was associated
with both greater LV mass and diastolic dysfunction. How-
ever, the authors did not examine the relationship between
individual metabolic risk factors and LV mass and function.
There is a well-established relationship between obesity and
increased LV mass.69
It is possible that no differences in LV mass index were
found between HIV + and HIV - groups with metabolic
complications because HIV - participants with metabolic
complications were significantly more obese than HIV +
participants with metabolic complications. However, in the
current study, the relationship between higher BMI and in-
creased LV mass index appeared to be present only in HIV +
individuals; therefore the presence of increased obesity in
the HIV - group may not have obscured potential differ-
ences in LVmass between groups. The presence of increased
LV mass (i.e., LV hypertrophy) is an important clinical
problem as it increases the risk for cardiovascular morbidity
and mortality, including the development of both systolic
and diastolic dysfunction, and progression to heart failure.70
Therefore, it appears that LV mass should be monitored in
HIV + individuals with well-controlled HIV infection with a
potential focus on modulation of obesity and elevated
blood pressure, two well-established risk factors for in-
creased LV mass.71
Althoughmoderate and severe LV systolic dysfunctionwas
not present in these participants, diastolic abnormalities are
clinically important. They play a fundamental role in the de-
velopment of heart failure, as they precede systolic failure in as
many as 40% of cases.72,73 Diastolic dysfunction has a marked
effect on exercise tolerance and quality of life,74 and when it
progresses to heart failure with preserved ejection fraction
(HFpEF, also known as diastolic heart failure), it has a mor-
tality similar to systolic heart failure.74 HFpEF is defined by
clinical signs or symptoms of heart failure, evidence of normal
left ventricular function, and evidence of diastolic dysfunc-
tion.75 Although mortality is lower in HFpEF than in those
with heart failure and reduced ejection fraction, the overall
absolute number of deaths in the general population attrib-
utable to HFpEF is likely higher due to the aging population.76
In addition, the presence of insulin resistance is associated
with a worse prognosis and increased risk for cardiovascular-
related death in those with HFpEF.77 Therefore, since 33% of
HIV-infected people with well-controlled viremia (as in the
current study) have evidence of diastolic dysfunction, close
monitoring of LV function appears to be warranted in HIV+
men and women with well-controlled HIV infection.
Women were underrepresented in this study and future
studies should examine differences in LV function and mass
between genders. Because this was a cross-sectional study
causality cannot be confirmed. Our conclusions cannot be ex-
tended to HIV+ individuals not taking cART or those with
greater plasma viremia. Groups were not perfectly matched on
metabolic risk factors; HIV- individuals with metabolic com-
plications had greater BMI, plasma glucose, and diastolic blood
pressure than HIV+ participants with metabolic complications.
Conclusions
Regardless of HIV status, men and women with metabolic
risk factors had worse indices of LV diastolic function in
comparison to those without risk factors. Although both the
presence of metabolic risk factors and HIV infection were
associated with lower diastolic function, there was no addi-
tive negative effect of HIV on diastolic function beyond the
effect of metabolic risk factors. Also, HIV was independently
associated with lower systolic function. Clinical monitoring
of LV function and implementation of interventions to im-
prove metabolic health and cardiovascular risk in individuals
with metabolic risk factors, regardless of HIV status, are
warranted.
Acknowledgments
We thank the participants for their altruism and patience,
the nursing staff of the Clinical Research Unit at Washington
University for their help in performing these studies, and the
nursing staff of the AIDS Clinical Trials Unit for recruitment
of the participants. This project was supported by National
Institutes of Health grants (DK074343 to W.T.C., AT003083,
DK049393, and DK059531 to K.E.Y., RR019508 to D.N.R., and
HL073120 to L.R.P.) and P30DK056341, DK020579, AI069495,
RR000954, UL1RR024992, and KL2RR024994 from the Na-
tional Center for Research Resources (NCRR) and NIH
Roadmap for Medical Research. Additional support was
provided by NIH grant S10RR024532 and a grant from the
Barnes-Jewish Hospital Foundation to the Cardiovascular
Imaging and Clinical Research Core Laboratory.
Author Disclosure Statement
No competing financial interests exist.
References
1. Himelman RB, Chung WS, Chernoff DN, Schiller NB, and
Hollander H: Cardiac manifestations of human immunode-
ficiency virus infection: A two-dimensional echocardio-
graphic study. J Am Coll Cardiol 1989;13:1030–1036.
2. Calabrese LH, Proffitt MR, Yen-Lieberman B, Hobbs RE, and
Ratliff NB: Congestive cardiomyopathy and illness related to
the acquired immunodeficiency syndrome (AIDS) associated
with isolation of retrovirus from myocardium. Ann Intern
Med 1987;107:691–692.
3. Palella FJ Jr, Delaney KM, Moorman AC, et al.: Declining
morbidity and mortality among patients with advanced
human immunodeficiency virus infection. HIV Outpatient
Study Investigators. N Engl J Med 1998;338:853–860.
4. Pugliese A, Isnardi D, Saini A, Scarabelli T, Raddino R, and
Torre D: Impact of highly active antiretroviral therapy in
HIV-positive patients with cardiac involvement. J Infect
2000;40:282–284.
5. Coudray N, de Zuttere D, Force G, et al.: Left ventricular
diastolic function in asymptomatic and symptomatic human
immunodeficiency virus carriers: An echocardiographic
study. Eur Heart J 1995;16:61–67.
6. Martinez-Garcia T, Sobrino JM, Pujol E, Galvez J, Benitez E,
and Giron-Gonzalez JA: Ventricular mass and diastolic
function in patients infected by the human immunodefi-
ciency virus. Heart 2000;84:620–624.
7. Cardoso JS, Moura B, Martins L, Mota-Miranda A, Rocha
Goncalves F, and Lecour H: Left ventricular dysfunction in
human immunodeficiency virus (HIV)-infected patients. Int
J Cardiol 1998;63:37–45.
8. Meng Q, Lima JA, Lai H, et al.: Use of HIV protease inhib-
itors is associated with left ventricular morphologic changes
HIV, METABOLIC COMPLICATIONS, AND THE HEART 1157
and diastolic dysfunction. J Acquir Immune Defic Syndr
2002;30:306–310.
9. Hsue PY, Hunt PW, Ho JE, et al.: Impact of HIV infection on
diastolic function and left ventricular mass. Circ Heart Fail
2010;3:132–139.
10. Schuster I, Thoni GJ, Ederhy S, et al.: Subclinical cardiac
abnormalities in human immunodeficiency virus-infected
men receiving antiretroviral therapy. Am J Cardiol
2008;101:1213–1217.
11. Nayak G, Ferguson M, Tribble DR, et al.: Cardiac diastolic
dysfunction is prevalent in HIV-infected patients. AIDS Pa-
tient Care STDS 2009;23:231–238.
12. Reinsch N, Kahlert P, Esser S, et al.: Echocardiographic
findings and abnormalities in HIV-infected patients: Results
from a large, prospective, multicenter HIV-heart study. Am J
Cardiovasc Dis 2011;1:176–184.
13. Blaylock JM, Byers DK, Gibbs BT, et al.: Longitudinal as-
sessment of cardiac diastolic function in HIV-infected pa-
tients. Int J STD AIDS 2012;23:105–110.
14. Mondy KE, Gottdiener J, Overton ET, et al.: High prevalence
of echocardiographic abnormalities among HIV-infected
persons in the era of highly active antiretroviral therapy.
Clin Infect Dis 2011;52:378–386.
15. Cade WT: Left ventricular dysfunction in human immuno-
deficiency virus infection. J Cardiometab Syndr 2008;3:
83–87.
16. Kelly KM, Tarwater PM, Karper JM, et al.: Diastolic dys-
function is associated with myocardial viral load in simian
immunodeficiency virus-infected macaques. AIDS 2012;26:
815–823.
17. Fiala M, Popik W, Qiao JH, et al.: HIV-1 induces cardiomy-
opathy by cardiomyocyte invasion and gp120, Tat, and cy-
tokine apoptotic signaling. Cardiovasc Toxicol 2004;4:
97–107.
18. Friis-Moller N, Sabin CA, Weber R, et al.: Combination an-
tiretroviral therapy and the risk of myocardial infarction. N
Engl J Med 2003;349:1993–2003.
19. Yarasheski KE, Tebas P, Sigmund C, et al.: Insulin resistance
in HIV protease inhibitor-associated diabetes. J Acquir Im-
mune Defic Syndr 1999;21:209–216.
20. Hadigan C, Miller K, Corcoran C, Anderson E, Basgoz N,
and Grinspoon S: Fasting hyperinsulinemia and changes in
regional body composition in human immunodeficiency
virus-infected women. J Clin Endocrinol Metab 1999;84:
1932–1937.
21. Grunfeld C, Kotler DP, Hamadeh R, Tierney A, Wang J, and
Pierson RN: Hypertriglyceridemia in the acquired immu-
nodeficiency syndrome. Am J Med 1989;86:27–31.
22. Calza L, Manfredi R, and Chiodo F: Dyslipidaemia associ-
ated with antiretroviral therapy in HIV-infected patients. J
Antimicrob Chemother 2004;53:10–14.
23. Safrin S and Grunfeld C: Fat distribution and metabolic
changes in patients with HIV infection. AIDS 1999;13:2493–
2505.
24. Carr A, Samaras K, Burton S, et al.: A syndrome of periph-
eral lipodystrophy, hyperlipidaemia and insulin resistance
in patients receiving HIV protease inhibitors. AIDS
1998;12:F51–58.
25. Lakka HM, Laaksonen DE, Lakka TA, et al.: The metabolic
syndrome and total and cardiovascular disease mortality in
middle-aged men. JAMA 2002;288:2709–2716.
26. Ninomiya JK, L’Italien G, Criqui MH, Whyte JL, Gamst A,
and Chen RS: Association of the metabolic syndrome with
history of myocardial infarction and stroke in the Third
National Health and Nutrition Examination Survey. Circu-
lation 2004;109:42–46.
27. Azevedo A, Bettencourt P, Almeida PB, et al.: Increasing
number of components of the metabolic syndrome and
cardiac structural and functional abnormalities—cross-
sectional study of the general population. BMC Cardiovasc
Disord 2007;7:17.
28. de las Fuentes L, Brown AL, Mathews SJ, et al.: Metabolic
syndrome is associated with abnormal left ventricular dia-
stolic function independent of left ventricular mass. Eur
Heart J 2007;28:553–559.
29. Gong HP, Tan HW, Fang NN, et al.: Impaired left ventricular
systolic and diastolic function in patients with metabolic
syndrome as assessed by strain and strain rate imaging.
Diabetes Res Clin Pract 2009;83:300–307.
30. Mogelvang R, Sogaard P, Pedersen SA, et al.: Cardiac dys-
function assessed by echocardiographic tissue Doppler im-
aging is an independent predictor of mortality in the general
population. Circulation 2009;119:2679–2685.
31. Grundy SM, Cleeman JI, Daniels SR, et al.: Diagnosis and
management of the metabolic syndrome: An American
Heart Association/National Heart, Lung, and Blood In-
stitute Scientific Statement. Circulation 2005;112:2735–
2752.
32. Mondy K, Overton ET, Grubb J, et al.: Metabolic syndrome
in HIV-infected patients from an urban, midwestern US
outpatient population. Clin Infect Dis 2007;44:726–734.
33. Samaras K, Wand H, Law M, Emery S, Cooper D, and Carr
A: Prevalence of metabolic syndrome in HIV-infected pa-
tients receiving highly active antiretroviral therapy using
International Diabetes Foundation and Adult Treatment
Panel III criteria: Associations with insulin resistance, dis-
turbed body fat compartmentalization, elevated C-reactive
protein, and [corrected] hypoadiponectinemia. Diabetes
Care 2007;30:113–119.
34. Adeyemi O, Rezai K, Bahk M, Badri S, and Thomas-Gossain
N: Metabolic syndrome in older HIV-infected patients: Data
from the CORE50 cohort. AIDS Patient Care STDS
2008;22:941–945.
35. Jerico C, Knobel H, Montero M, et al.: Metabolic syndrome
among HIV-infected patients: Prevalence, characteristics,
and related factors. Diabetes Care 2005;28:132–137.
36. Alencastro PR, Wolff FH, Oliveira RR, et al.: Metabolic
syndrome and population attributable risk among HIV/
AIDS patients: Comparison between NCEP-ATPIII, IDF and
AHA/NHLBI definitions. AIDS Res Ther 2012;9:29.
37. Bonfanti P, Giannattasio C, Ricci E, et al.: HIV and metabolic
syndrome: A comparison with the general population. J
Acquir Immune Defic Syndr 2007;45:426–431.
38. Bajraktari G, Koltai MS, Ademaj F, et al.: Relationship be-
tween insulin resistance and left ventricular diastolic dys-
function in patients with impaired glucose tolerance and
type 2 diabetes. Int J Cardiol 2006;110:206–211.
39. Ryan MC, Fenster Farin HM, Abbasi F, and Reaven GM:
Comparison of waist circumference versus body mass index
in diagnosing metabolic syndrome and identifying appar-
ently healthy subjects at increased risk of cardiovascular
disease. Am J Cardiol 2008;102:40–46.
40. Alberti KG, Eckel RH, Grundy SM, et al.: Harmonizing the
metabolic syndrome: A joint interim statement of the Inter-
national Diabetes Federation Task Force on Epidemiology
and Prevention; National Heart, Lung, and Blood Institute;
American Heart Association; World Heart Federation;
International Atherosclerosis Society; and International
1158 CADE ET AL.
Association for the Study of Obesity. Circulation
2009;120:1640–1645.
41. Reeds DN, Yarasheski KE, Fontana L, et al.: Alterations in
liver, muscle, and adipose tissue insulin sensitivity in men
with HIV infection and dyslipidemia. Am J Physiol En-
docrinol Metab 2006;290:E47–E53.
42. Schiller NB, Shah PM, Crawford M, et al.: Recommendations
for quantitation of the left ventricle by two-dimensional
echocardiography. American Society of Echocardiography
Committee on Standards, Subcommittee on Quantitation of
Two-Dimensional Echocardiograms. J Am Soc Echocardiogr
1989;2:358–367.
43. Lang RM, Bierig M, Devereux RB, et al.: Recommendations
for chamber quantification: A report from the American
Society of Echocardiography’s Guidelines and Standards
Committee and the Chamber Quantification Writing Group,
developed in conjunction with the European Association of
Echocardiography, a branch of the European Society of
Cardiology. J Am Soc Echocardiogr 2005;18:1440–1463.
44. Quinones MA, Otto CM, Stoddard M, Waggoner A, and
Zoghbi WA: Recommendations for quantification of Dopp-
ler echocardiography: A report from the Doppler Quantifi-
cation Task Force of the Nomenclature and Standards
Committee of the American Society of Echocardiography. J
Am Soc Echocardiogr 2002;15:167–184.
45. de las Fuentes L, Waggoner AD, Brown AL, and Davila-
Roman VG: Plasma triglyceride level is an independent
predictor of altered left ventricular relaxation. J Am Soc
Echocardiogr 2005;18:1285–1291.
46. Peterson LR, Waggoner AD, Schechtman KB, et al.: Altera-
tions in left ventricular structure and function in young
healthy obese women: Assessment by echocardiography
and tissue Doppler imaging. J Am Coll Cardiol
2004;43:1399–1404.
47. Nagueh SF, Middleton KJ, Kopelen HA, Zoghbi WA, and
Quinones MA: Doppler tissue imaging: A noninvasive
technique for evaluation of left ventricular relaxation and
estimation of filling pressures. J Am Coll Cardiol
1997;30:1527–1533.
48. Oki T, Tabata T, Yamada H, et al.: Clinical application of
pulsed Doppler tissue imaging for assessing abnormal left
ventricular relaxation. Am J Cardiol 1997;79:921–928.
49. Brucks S, Little WC, Chao T, et al.: Contribution of left
ventricular diastolic dysfunction to heart failure regardless
of ejection fraction. Am J Cardiol 2005;95:603–606.
50. Munagala VK, Jacobsen SJ, Mahoney DW, Rodeheffer RJ,
Bailey KR, and Redfield MM: Association of newer diastolic
function parameters with age in healthy subjects: A popu-
lation-based study. J Am Soc Echocardiogr 2003;16:1049–
1056.
51. Peterson LR, Saeed IM, McGill JB, et al.: Sex and type 2
diabetes: Obesity-independent effects on left ventricular
substrate metabolism and relaxation in humans. Obesity
(Silver Spring) 2012;20:802–810.
52. Chai Y, Zhang DM, and Lin YF: Activation of cGMP-
dependent protein kinase stimulates cardiac ATP-sensitive
potassium channels via a ROS/calmodulin/CaMKII signal-
ing cascade. PLoS One 2011;6:e18191.
53. Zhou YT, Grayburn P, Karim A, et al.: Lipotoxic heart dis-
ease in obese rats: Implications for human obesity. Proc Natl
Acad Sci USA 2000;97:1784–1789.
54. Cade WT, Reeds DN, Overton ET, et al.: Effects of human
immunodeficiency virus and metabolic complications on
myocardial nutrient metabolism, blood flow, and oxygen
consumption: A cross-sectional analysis. Cardiovasc Diabe-
tol 2011;10:111.
55. Kan H, Xie Z, and Finkel MS: HIV gp120 enhances NO
production by cardiac myocytes through p38 MAP kinase-
mediated NF-kappaB activation. Am J Physiol Heart Circ
Physiol 2000;279:H3138–3143.
56. Kan H, Xie Z, and Finkel MS: p38 MAP kinase-mediated
negative inotropic effect of HIV gp120 on cardiac myocytes.
Am J Physiol Cell Physiol 2004;286:C1–7.
57. Kan H, Xie Z, and Finkel MS: iPLA2 inhibitor blocks nega-
tive inotropic effect of HIV gp120 on cardiac myocytes. J Mol
Cell Cardiol 2006;40:131–137.
58. Berzingi C, Chen F, and Finkel MS: p38 MAP kinase inhib-
itor prevents diastolic dysfunction in rats following HIV
gp120 injection in vivo. Cardiovasc Toxicol 2009;9:142–150.
59. Espinola-Klein C, Gori T, Blankenberg S, and Munzel T:
Inflammatory markers and cardiovascular risk in the meta-
bolic syndrome. Front Biosci 2011;16:1663–1674.
60. Kan H and Finkel MS: Inflammatory mediators and re-
versible myocardial dysfunction. J Cell Physiol 2003;195:
1–11.
61. Lugnier C: PDE inhibitors: A new approach to treat meta-
bolic syndrome? Curr Opin Pharmacol 2011;11:698–706.
62. Raidel SM, Haase C, Jansen NR, et al.: Targeted myocardial
transgenic expression of HIV Tat causes cardiomyopathy
and mitochondrial damage. Am J Physiol Heart Circ Physiol
2002;282:H1672–1678.
63. Fang Q, Kan H, Lewis W, Chen F, Sharma P, and Finkel MS:
Dilated cardiomyopathy in transgenic mice expressing HIV
Tat. Cardiovasc Toxicol 2009;9:39–45.
64. Lewis W, Miller YK, Haase CP, et al.: HIV viral protein R
causes atrial cardiomyocyte mitosis, mesenchymal tumor,
dysrhythmia, and heart failure. Lab Invest 2005;85:182–192.
65. Lubega S, Zirembuzi GW, and Lwabi P: Heart disease
among children with HIV/AIDS attending the paediatric
infectious disease clinic at Mulago Hospital. Afr Health Sci
2005;5:219–226.
66. Okoromah CA, Ojo OO, and Ogunkunle OO: Cardiovas-
cular dysfunction in HIV-infected children in a sub-Saharan
African country: Comparative cross-sectional observational
study. J Trop Pediatr 2012;58:3–11.
67. Fisher SD, Easley KA, Orav EJ, et al.: Mild dilated cardio-
myopathy and increased left ventricular mass predict mor-
tality: The prospective P2C2 HIV Multicenter Study. Am
Heart J 2005;150:439–447.
68. de Simone G, Palmieri V, Bella JN, et al.: Association of left
ventricular hypertrophy with metabolic risk factors: The
HyperGEN study. J Hypertens 2002;20:323–331.
69. de las Fuentes L, Waggoner AD, Mohammed BS, et al.: Effect
of moderate diet-induced weight loss and weight regain on
cardiovascular structure and function. J Am Coll Cardiol
2009;54:2376–2381.
70. Levy D, Garrison RJ, Savage DD, Kannel WB, and Castelli
WP: Prognostic implications of echocardiographically de-
termined left ventricular mass in the Framingham Heart
Study. N Engl J Med 1990;322:1561–1566.
71. Norton GR, Majane OH, Libhaber E, et al.: The relationship
between blood pressure and left ventricular mass index
depends on an excess adiposity. J Hypertens 2009;27:1873–
1883.
72. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL,
and Redfield MM: Trends in prevalence and outcome of
heart failure with preserved ejection fraction. N Engl J Med
2006;355:251–259.
HIV, METABOLIC COMPLICATIONS, AND THE HEART 1159
73. Yamamoto K, Redfield MM, and Nishimura RA: Analysis of
left ventricular diastolic function. Heart 1996;75:27–35.
74. Zile MR and Brutsaert DL: New concepts in diastolic dys-
function and diastolic heart failure: Part I: Diagnosis, prog-
nosis, and measurements of diastolic function. Circulation
2002;105:1387–1393.
75. Lam CS, Donal E, Kraigher-Krainer E, and Vasan RS: Epi-
demiology and clinical course of heart failure with preserved
ejection fraction. Eur J Heart Fail 2011;13:18–28.
76. Gottdiener JS, McClelland RL, Marshall R, et al.: Outcome of
congestive heart failure in elderly persons: influence of left
ventricular systolic function. The Cardiovascular Health
Study. Ann Intern Med 2002;137:631–639.
77. MacDonald MR, Petrie MC, Varyani F, et al.: Impact of di-
abetes on outcomes in patients with low and preserved
ejection fraction heart failure: An analysis of the Cande-
sartan in Heart failure: Assessment of Reduction in Mortal-




Program in Physical Therapy and Department of Medicine
Washington University School of Medicine
4444 Forest Park Boulevard
St. Louis, Missouri 63108-2212
E-mail: tcade@wustl.edu
1160 CADE ET AL.
